Impact of High-Risk Mutations and Treatment Intensity in Accelerated-Phase Blast-Phase MPN Without Adverse-Risk Karyotype and TP53
Current Oncology · 12.07.2026 · 33 (7) · 419
DOI: 10.3390/curroncol33070419 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, online erschienen am 12.07.2026. Verfasst von Verna Cheung und 8 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada. Hauptthemen laut MEDLINE: Mutation, Tumor Suppressor Protein p53, Myeloproliferative Disorders. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The prognostic significance of myelodysplasia-related gene mutations (MDS-RGMs), defined by the ELN 2022 classification and Mutation-Enhanced International Prognostic Score System high-risk mutations (MIPSS70-HRM), in accelerated-phase (AP) and blast-phase (BP) myeloproliferative neoplasms (MPNs) remains unclear. We conducted a retrospective study of 101 AP/BP MPN patients with intermediate-risk cytogenetics, excluding TP53 mutations and adverse-risk karyotypes. We evaluated whether MDS-RGM or MIPSS70-HRM predicted treatment response, overall survival (OS), or disease-free survival (DFS) and whether treatment intensity affected OS. Patients included AP (29.7%) and BP (70.3%), with 55% receiving intensive therapy. Allogeneic stem cell transplant (ASCT) significantly improved OS (HR 0.31, 95% CI 0.19–0.50; p < 0.0001), as did AP versus BP at transformation (HR: 0.43, 95% CI 0.26–0.73; p = 0.0016). Among patients ≤ 70 years with ECOG 0–1 (N = 77), ASCT and reversion to chronic-phase MPN (cMPN) were associated with longer OS (p < 0.0001 and p = 0.0475). Treatment intensity alone did not significantly affect OS (p = 0.1991).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
- Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON M5T 1P8, Canada.
- Department of Biostatistics, University Health Network, Toronto, ON M5G 1X6, Canada.
- Division of Biostatistics, DLSPH, University of Toronto, Toronto, ON M5T 3M7, Canada.
ORCID-Profile: Verna Cheung, Eshetu G Atenafu, Hassan Sibai
Zitieren
APA
Cheung, V., Davidson, M., Atenafu, E. G., Arruda, A., Claudio, J. O., Bankar, A., Maze, D., Gupta, V., & Sibai, H. (2026). Impact of High-Risk Mutations and Treatment Intensity in Accelerated-Phase Blast-Phase MPN Without Adverse-Risk Karyotype and TP53. Current Oncology, 33(7), 419. https://doi.org/10.3390/curroncol33070419
Vancouver
Cheung V, Davidson M, Atenafu EG, Arruda A, Claudio JO, Bankar A, et al. Impact of High-Risk Mutations and Treatment Intensity in Accelerated-Phase Blast-Phase MPN Without Adverse-Risk Karyotype and TP53. Current Oncology. 2026;33(7):419. doi:10.3390/curroncol33070419
BibTeX
@article{Cheung2026,
author = {Cheung, Verna and Davidson, Marta and Atenafu, Eshetu G and Arruda, Andrea and Claudio, Jaime O and Bankar, Aniket and Maze, Dawn and Gupta, Vikas and Sibai, Hassan},
title = {Impact of High-Risk Mutations and Treatment Intensity in Accelerated-Phase Blast-Phase MPN Without Adverse-Risk Karyotype and TP53},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {7},
pages = {419},
doi = {10.3390/curroncol33070419}
}
EUVIMED